Development of an α-synuclein knockdown peptide and evaluation of its efficacy in Parkinson’s disease models
Jin et al develop and characterise a blood-brain barrier and plasma membrane-permeable α-synuclein knockdown peptide, Tat-βsyn-degron. In two mouse models of Parkinson’s disease, they show that Tat-βsyn-degron decreases α-synuclein aggregates and microglial activation as well as reducing neuronal da...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/63d676340fd343489fc159532b920ece |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Jin et al develop and characterise a blood-brain barrier and plasma membrane-permeable α-synuclein knockdown peptide, Tat-βsyn-degron. In two mouse models of Parkinson’s disease, they show that Tat-βsyn-degron decreases α-synuclein aggregates and microglial activation as well as reducing neuronal damage and motor impairment. This study demonstrates the therapeutic potential of Tat-βsyn-degron in Parkinson’s disease treatment. |
|---|